DNA methylation of the SPRY2 promoter is associated with reduced SPRY2 expression in patient lymphoma samples. (A) SPRY2 expression normalized to GAPDH expression was assessed by quantitative PCR in 7 DLBCLs and 1 BL, and the DNA methylation status for each tumor was assessed by MSP. The top and bottom bands correspond to PCR products amplified by primers specific for methylated (M) or unmethylated (U) CpG sites after bisulfite conversion. Estimated percentage of tumor cells in each sample is shown in parentheses. (B) GBS of a CpG-rich region located between −163 and +25 in the SPRY2 promoter in DLBCL5, DLBCL7, and BL1 patient samples. Each row represents the sequence of an individual clone. ○ represents unmethylated CpG sites; ●, methylated CpG sites.